Related by context. All words. (Click for frequent words.) 64 AGENDA Trial global 64 Synexus ® 61 International Nasdaq PRAI 61 ExCell study 60 investigational hepatitis C 60 Clinicaltrials.gov 60 OVATURE 59 alvespimycin 59 TRO# 59 Phase IIIb clinical 59 rALLy clinical trial 59 budesonide MMX Phase III 59 phase IIa clinical 59 clinicaltrials 59 ELACYT 59 MAGE A3 ASCI 58 Phase 2b MATRIX 58 NCCTG 58 www.careers.edwardjones.com 58 ALN VSP Phase 57 ZACTIMA 57 PANVAC VF 57 viral kinetic 57 EMPHASIS HF trial 57 tramiprosate Alzhemed TM 57 VITAL Trial 57 CALGB 57 Phase IIb III 57 Phase Ib II 57 imetelstat GRN#L 57 LHRH receptor positive 57 pharmacogenomic translational research 57 HireAbility.com LLC 57 NOX E# 57 Phase #b/#a clinical 57 PRESEPT 57 Phase III TRIST 57 rALLy trial 57 ALSYMPCA 57 LibiGel Phase III 57 visit http:/www.clinicaltrials.gov/ 57 drug Inspra 56 Alzhemed TM 56 neratinib 56 sapacitabine CYC# 56 ONCONASE R 56 Tesmilifene 56 phase IIb clinical 56 TNFerade TM 56 GRN# 56 phase III ACCLAIM 56 Phase III ADT 56 oral talactoferrin 56 Canvaxin TM 56 CRLX# 56 Phase 2b RESTORE CLI 56 BR.# 56 StemEx R 56 ThermoDox ® clinical 56 ABSORB clinical 56 refractory metastatic 56 GALAXY Programme 56 mSEPT9 biomarker 56 SUCCEED trial 56 Phase III HEAT 56 brentuximab vedotin SGN 56 PDX pralatrexate 56 REGENESIS Phase IIb 56 Virulizin ® 56 ToGA 56 CEQ# 56 REVIVE Diabetes 56 Phase III randomized controlled 56 immunotherapeutic approaches 56 metastatic pancreatic 56 pelvic malignancies 55 phase IIb trial 55 ALTTO 55 SCIB1 55 DF HCC 55 Nanobody R 55 NO# [002] 55 PARTNER Trial 55 CHAMPION PCI 55 Allovectin 7 55 deCODE ProstateCancer TM 55 LibiGel testosterone gel 55 vaccine Stimuvax 55 Phase Ib study 55 confirmatory Phase IIIb 55 dirucotide MBP# 55 LibiGel ® testosterone gel 55 oncology virology 55 ICON7 55 AIMM trial 55 Insegia 55 Archexin 55 clinical trial 55 including eniluracil ADH 55 Annamycin 55 Dendreon investigational 55 phase IIb 55 forodesine 55 elacytarabine 55 Allovectin 7 ® 55 phase III SIMPADICO 55 Phase IIb clinical trials 55 APEX PD 55 oral ridaforolimus 55 novel therapeutic antibodies 55 assessing T DM1 55 Phase 2a clinical 55 StemEx 55 Liposomal Grb 2 54 UVIDEM 54 HQK 54 regorafenib 54 acyclovir Lauriad R 54 http:/www.vivus.com 54 IMA# 54 Robert Motzer MD 54 genomic biomarker 54 Tarvacin TM 54 EDEMA3 54 HCD# [002] 54 therapeutic monoclonal antibody 54 REVEAL Registry 54 solid tumors ZYBRESTAT 54 targeting miR 54 ovarian endometrial 54 Fx #A 54 phase IIb study 54 iii GTx 54 lintuzumab SGN 54 Oral NKTR 54 placebo controlled Phase III 54 ACCEDE 54 Empatic ™ 54 LEUKINE 54 HPTN 54 OvaRex R 54 NPC 1C 54 NABTT 54 ENGAGE AF TIMI 54 alemtuzumab Campath 54 CA9 SCAN 54 QOPI 54 lorcaserin Phase 54 multicenter Phase II 54 blinded randomized placebo controlled 54 EchoCRT 54 Trofex 54 ASCO abstract 54 Integrium 54 clinical pharmacology studies 54 Troxatyl 54 CEL SCI Phase III 54 includes OpenHire ™ 54 YONDELIS 54 non nucleoside inhibitor 54 phase Ib 54 exploratory Phase IIa 54 dose escalation phase 54 mertansine 54 lumiliximab 54 Matrix Phase 2b 54 pharmacokinetic pharmacodynamic 54 GetGoal Phase III 54 tremelimumab 54 CLIRS trial 54 commercialize CorMedix drug 54 recombinant PSMA vaccine 54 midstage clinical 54 Phase Ib clinical 53 R#/MEM # 53 DCVax R 53 midstage trials 53 Provectus Pharmaceuticals specializes 53 multicenter Phase 53 Phase 1a clinical 53 Hedgehog antagonist 53 randomized controlled Phase 53 BCIRG 53 TNFerade ™ 53 Kosan dependence 53 Phase #/#a 53 registrational 53 Aurexis 53 drug NP2 Enkephalin 53 OncoVex 53 rALLy 53 AdhTAP 53 Cloretazine ® 53 AEG# 53 please visit http:/www.sunesis.com 53 AGGRASTAT ® tirofiban hydrochloride 53 Aplidin 53 BRAF mutated 53 PDE# inhibitors 53 Diamyd ® 53 LUMINATE 53 Manja Bouman CEO 53 dermatology biopharmaceutical company 53 lintuzumab 53 BRIM3 53 lorvotuzumab mertansine 53 miconazole Lauriad 53 DEB# 53 gastro intestinal inflammation 53 Stage IIIb 53 aide Nathan Maxcey 53 metastatic renal cell 53 Proellex TM 53 intravenous RSD# 53 Phase Ia 53 Phase IIb trial 53 EOquin 53 Genasense ® 53 Onrec.com EXPO 53 Phase IIa clinical 53 investigational therapies 53 Oncotype DX colon cancer 53 NP2 Enkephalin 53 MVA MUC1 IL2 53 clevidipine 53 Zemplar Capsules 53 European Sepsis Trial 53 BARI 2D 53 Phase 2a trial 53 Phase Ib IIa 53 GVAX ® 53 relapsed MM 53 CYT# potent vascular disrupting 53 OLYMPIA registry 53 BrachySil TM 53 CB2 selective receptor agonist 53 TOCOSOL Camptothecin 53 recurrent glioma 53 relapsed leukemia 53 delivers fluocinolone acetonide FA 53 management biostatistical analysis 53 metastatic bladder 53 preclinically 53 Institute DCRI 53 AGGRASTAT R tirofiban hydrochloride 53 Phase 2b clinical 53 Canvaxin 53 zanolimumab 53 randomized Phase IIb 53 enzastaurin 53 CMV vaccine 53 trastuzumab DM1 T DM1 53 Hedgehog inhibitor 53 Swiftpro Ltd. 52 RE LY trial 52 PI3K/Akt pathway inhibitor 52 PDE4 inhibitor 52 TKM PLK1 52 pain palliation 52 deCODE AF TM 52 Aurora kinase inhibitor 52 RhuDex R 52 confirmatory clinical 52 DermaVir Patch 52 multicenter phase 52 PEARL SC 52 ophthalmology dermatology cardiovascular disease 52 Medidur TM FA 52 HCV SPRINT 52 GLP toxicology studies 52 malignant pleural mesothelioma 52 Phase III VISTA 52 RhuDex ® 52 farletuzumab 52 multicenter Phase III 52 phase IIIb 52 Tykerb lapatinib 52 thrombin inhibiting aptamer 52 TACI Ig 52 galiximab 52 drug GAP #B# 52 CYT# vascular disrupting 52 talactoferrin 52 TransMID 52 Phase 1b clinical trials 52 recurrent glioblastoma multiforme 52 PORxin TM platforms 52 Bexion 52 BRIM2 52 HGS# 52 HEPLISAV TM hepatitis B 52 HORIZONS AMI trial 52 anti PlGF 52 glucokinase activator 52 ASCEND HF 52 APEX AMI trial 52 number NCT# ClinicalTrials.gov 52 novel oral anticoagulant 52 Asentar 52 Aflibercept 52 Pyridorin 52 MOZOBIL 52 vivo toxicology 52 HORIZONS AMI 52 Transgene therapeutic 52 Panzem R NCD 52 candidates Dyloject TM 52 Lucanix R 52 Phase #/#a trial 52 CaPSURE 52 antibody MAb 52 EVIZON TM squalamine lactate 52 NPWH 52 Triapine R 52 Prostate Lung Colorectal 52 placebo controlled clinical 52 Angiocept 52 INSPIRE Trial Phase III 52 sunitinib malate 52 ELCAP 52 LibiGel ® 52 CCR5 antagonist 52 YAKIMA WA Psychiatrist 52 Steven R. Deitcher 52 HCV polymerase 52 MelaFind pivotal 52 Kendle NASDAQ KNDL 52 pafuramidine 52 VitiGam TM 52 TMC# [002] 52 neurology immunology 52 unique alkylating agent 52 Advaxis Phase 52 Futurestep subsidiary 52 pharmacokinetic PK study 52 fidaxomicin Phase 3 52 Phase IIa trial 52 Prednisone Against Refractory 52 IMPACT DCM clinical 52 Memryte 52 pivotal bioequivalence 52 Myocet 52 pivotal Phase III 52 phase IIa 52 NCCN Compendium 52 treatment naive genotype 52 Factor VIIa 52 TBC# 52 Quinamed 52 kidney urologic 52 Phase III multicenter 52 bardoxolone 52 antiretroviral naïve 52 motesanib 52 CRMD# 52 AAG geldanamycin analog 52 wide receiver Kenbrell Thompkins 52 ABSORB trial 52 Allovectin 7 R 52 R sorafenib tablets 52 ALN HTT 52 AIR CF3 52 IMC #B 52 BLA filing 52 velafermin 52 adrenergic regulation 52 multicenter clinical 52 Phase IIIb 52 TPI ASM8 52 predictive biomarkers 52 HER2 positive metastatic breast 51 Screening Trial DMIST 51 randomized Phase III 51 Phase IIa trials 51 pertuzumab 51 ENDEAVOR III 51 OvaRex 51 cellular immunotherapy 51 elotuzumab 51 Phase Ib IIa clinical 51 GW# [003] 51 Degarelix 51 Dacogen injection 51 ADVANCE PD 51 dose intramuscular 51 Phase IIb clinical 51 HuLuc# 51 TLK# 51 Albuferon albinterferon alfa 2b 51 LymphoStat B TM 51 midstage studies 51 apricitabine ATC 51 AVAiL 51 MAXY alpha 51 Phase 2b study 51 cetrorelix pamoate 51 3 registrational trial 51 Nasal spray flu 51 unresectable tumors 51 NSABP C 51 vidofludimus 51 evaluating Actimmune 51 relapsing remitting MS RRMS 51 PRESEPT Study 51 entinostat 51 confirmatory Phase 3 51 MYTHOS trial 51 haematological cancers 51 Oglemilast 51 Teplizumab 51 bladder ovarian 51 hypoxia activated prodrug 51 Nexavar sorafenib 51 riociguat 51 Phase III Pivotal 51 prognostic biomarkers 51 SinuNase ™ 51 Bayer HealthCare Onyx Pharmaceuticals 51 Urocortin 2 51 Zoraxel 51 IAP inhibitor 51 CLIRS 51 Li Fraumeni 51 radiolabeled TM# 51 AVADO 51 OMP #M# 51 BHT DNA 51 Phase III clinical 51 Renal Cell Carcinoma RCC 51 Proxinium TM 51 RE LY ® 51 oral deforolimus 51 Nasdaq ONXX today 51 OncoVEX 51 receptor tyrosine kinase inhibitor 51 Generx ™ 51 NSABP 51 leading oral taxane 51 Cloretazine 51 dexanabinol 51 cathepsin K inhibitor 51 THR beta agonist 51 HuCNS SC ® 51 clinical trials 51 BRAF inhibitor 51 Solazed 51 TG MV 51 Fibrillex TM 51 TOCOSOL R 51 DCVax ® Brain 51 Phase III clinical trials 51 HuCAL antibodies 51 previously untreated follicular 51 commercialize deforolimus 51 CR# vcMMAE 51 forodesine hydrochloride 51 Plenaxis TM 51 MKC# MT 51 Cloretazine R 51 KRN# 51 systemic ALCL 51 ongoing Phase 1b 51 ENRICH trial 51 QNEXA ® 51 OMAPRO 51 inhibit metastasis 51 Phase 2b clinical trials 51 oral prodrug 51 candidate TNFerade biologic 51 COSIRA trial 51 cardio metabolic diseases 51 limiting generalizability 51 HuMax EGFr 51 ONTARGET 51 HuMax TAC 51 registrational trial 51 MIS# 51 ANCHOR trial 51 Wisconsin Sleep Cohort 51 ENESTnd 51 TREX Recruitment 51 dacetuzumab 51 double blinded randomized 51 subcutaneous PRO 51 Ostabolin C TM 51 ClinicalTrials.gov Identifier NCT# 51 SYN# 51 ataluren 51 Phase IIIb study 51 JAK inhibitor 51 Daclizumab 51 immunotherapeutic vaccine 51 recurrent metastatic 51 Raf kinase inhibitor 51 ISEL 51 EVEREST II 51 OMP #R# 51 PrevOnco ™ 51 opioid naive 51 Azedra TM 51 refractory CLL 51 dose cohort 51 Pagoclone 51 Neuradiab 51 hematological malignancy 51 Aryplase 51 Exherin TM 51 Phase 1b trial 51 paclitaxel Taxol R 51 DPX Survivac 51 NYP-NEWS 51 rindopepimut 51 Ixempra 50 Phase #b/#a 50 Triapine 50 bevirimat Study 50 RIGScan 50 M# rationally 50 exemestane Aromasin 50 SNT MC# 50 dose escalation clinical 50 AspenBio 50 Dr. McHutchison 50 clinical endocrinologists 50 RRMS patients 50 Ceflatonin R 50 trastuzumab DM1 50 GRNVAC1 50 orally inhaled migraine 50 OvaRex ® MAb 50 GLPG# 50 pafuramidine maleate 50 Phase III psoriasis 50 HIV coinfected 50 antiangiogenic therapy 50 Theratope 50 depsipeptide 50 BEXXAR 50 EmbraceAC 50 PSN# [002] 50 cabozantinib 50 placebo controlled randomized 50 EMPOWER TM 50 COU AA 50 seliciclib CYC# 50 OnDose TM 50 Raloxifene STAR 50 next generation URAT1 50 unblinding 50 neurology gastroenterology 50 Teriflunomide 50 Prostate AdenoCarcinoma Treatment 50 ACAPODENE TM 50 BioNumerik 50 compound AEZS 50 TransVax ™ 50 PLX MS 50 fostamatinib 50 AVN# [001] 50 Tectin TM 50 prospective multicentre 50 Phase 2a clinical trials 50 PSMA ADC 50 biliary cancer 50 relapsed MCL 50 goserelin 50 CIMZIA TM certolizumab pegol 50 prospectively defined 50 phase IIb III 50 maximally tolerated dose 50 Josh Helmholdt 50 olaparib 50 DAPT Study 50 Omigard 50 Phase 2a preventative 50 GERD migraine headaches 50 BLA submission 50 MORAb 50 generation PNP inhibitor 50 confirmatory pivotal 50 pharmacodynamic effects 50 thorough QT 50 opioid induced bowel dysfunction 50 CRACM 50 TOCOSOL Paclitaxel 50 allergic airway inflammation 50 Phase Ib 50 budesonide MMX ® 50 PHX# 50 vemurafenib 50 MGMT methylation 50 humanised monoclonal antibody 50 double blinded placebo 50 BrachySil ™ 50 Calmare pain 50 fusion enhancers 50 website http:/www.celsion.com 50 XL# SAR# 50 AQ4N 50 Sorafenib HCC Assessment 50 Amgen Neulasta ® 50 gynecologic malignancies 50 relapsed multiple myeloma 50 subcutaneous formulation 50 Amrubicin 50 Successfully Completes Phase 50 EOquin TM 50 PROSTVAC VF 50 OncoVEX GM CSF 50 Laheru 50 motesanib diphosphate 50 IMiDs ® compound 50 SILENOR TM doxepin HCl 50 postmarketing adverse 50 ganetespib 50 grievances Boucek 50 multicenter prospective 50 tumors GIST 50 BRAF mutant 50 PROSTVAC TM 50 stage IIIb IV 50 progressive metastatic prostate 50 PF # [002] 50 clinical 50 refractory colorectal cancer 50 vosaroxin 50 EFAPROXYN 50 IMPDH inhibitor 50 VNP#M 50 Avastin adjuvant 50 product TNFerade TM 50 SYMMETRY trial 50 sNDA submission 50 randomized multicenter trial 50 LAS# [002] 50 candidate REP# 50 EndoTAGTM 1 50 OncologySTAT 50 TKM ApoB 50 cangrelor 50 RESTORE CLI trial 50 GAMMAGARD 50 targeted radiotherapeutic 50 Phase IIb REGENESIS 50 prospective observational 50 bardoxolone methyl 50 APEX AMI 50 FOLOTYN ® 50 www.hematology.org 50 oral PTH 50 Vertex hepatitis C 50 Tarceva TM 50 Telintra 50 NV1FGF 50 drug GLPG# 50 ASONEP TM 50 neoadjuvant treatment 50 oncolytic virus therapies 50 dexpramipexole 50 Hepatocellular Carcinoma HCC 50 TRIOLEX HE# APOPTONE HE# 50 Raptiva R 50 varespladib 50 KIACTA ™ 50 vascular disrupting agent 50 CALGB # [002] 50 PD2i CA 50 adjuvant endocrine therapy 50 GENASIS 50 Silenor ® 50 class mGluR5 inhibitor 50 hepatologists 50 reslizumab 50 resectable pancreatic cancer 50 MedPredict 50 Tarvacin Anti Cancer 50 Specifid 50 AIM HIGH 50 IRX 2 50 tramiprosate ALZHEMED TM 50 GVAX R 50 Phase 2b trial 50 RSD# oral 50 MGd 50 PROPEL trial 50 Ophena 50 Capesaris 50 Al Suwailmi 50 LAB CGRP 50 prelicensure 50 LUX Lung 50 preclinical efficacy 50 Delcath System 50 Phase IIb trials 50 INS# [001] 50 aflibercept VEGF Trap 50 IMiDs R 50 landmark ATHENA 50 abiraterone 50 neuro oncologists 50 ponatinib 50 prospective randomized placebo 50 Inhaled nitric oxide 50 novel immunotherapies 50 CIMZIA ™ 50 tumor histology 50 cervical prostate 50 DU #b 50 aflibercept 50 drug Treanda 49 EMPOWER ™ 49 postdoctoral trainees 49 romidepsin 49 MARVEL Trial 49 chemoprevention trials 49 ZOLINZA 49 apaziquone 49 Androxal TM 49 initiated Phase Ib 49 CyPath ® diagnostic 49 Vitaxin 49 metastatic colorectal 49 TASKi2 49 follicular Non Hodgkin 49 omacetaxine mepesuccinate 49 efaproxiral 49 non hodgkin lymphoma 49 SUTENT ® 49 ancrod 49 brivaracetam 49 TEC #OL 49 personalized immunotherapy 49 JAK#/JAK# inhibitor CYT# 49 thetreatment 49 CLL8 49 Onconase 49 surgeons oncologists 49 EQUIP OB 49 Bellicum 49 Phase 2b kidney transplant 49 recurrent epithelial ovarian 49 Phase IIb kidney transplant 49 evaluating REVLIMID 49 Wyeth Progenics 49 please visit www.brighamandwomens.org 49 Provacel 49 Traficet EN 49 CAMPATH 49 CCR9 antagonist 49 prognostic markers 49 relapsed acute lymphoblastic 49 SIMPADICO 49 fosbretabulin 49 APTIVUS R 49 Medacs Healthcare 49 BNC# 49 ABSSSI 49 dermatology biopharmaceutical 49 HeFT 49 non nucleoside HCV 49 teriflunomide 49 Phase lll 49 FREE Appointments Seminars 49 BEXXAR Therapeutic Regimen 49 torezolid phosphate 49 Corlux 49 KNS # 49 psoriasis inflammatory bowel 49 ofatumumab HuMax CD# 49 oral ghrelin agonist 49 AA Amyloidosis 49 multicenter trials 49 candidate deforolimus 49 visit www.rtanswers.org 49 recurrent glioblastoma multiforme GBM 49 KuDOS 49 Ceflatonin 49 Angiolix 49 phase 2a 49 BAY #-# 49 indibulin 49 drug figitumumab 49 PEG SN# 49 Trofex TM 49 huC# DM4 49 evaluating Nexavar 49 docetaxel Taxotere R 49 Martin Nicklasson CEO 49 apremilast 49 dose escalation trial 49 histone deacetylase 49 de novo kidney transplant 49 Fibrin Pad 49 autologous hematopoietic stem cell 49 placebo controlled Phase 49 TroVax ® 49 Akt inhibitor 49 CERVARIX 49 oral picoplatin 49 Phase 1b 49 enroller 49 Lynn Schuchter 49 Zenvia ™ 49 humanized therapeutic 49 tezampanel NGX# 49 intradermal injections 49 solid organ transplantation 49 PTK# 49 ReN# 49 IMPACT DCM 49 MET inhibitor 49 Romidepsin 49 BST CarGel R 49 DCVax 49 KRYSTEXXA TM pegloticase 49 Opexa 49 Phase III randomized 49 crizotinib PF # 49 ritonavir boosted danoprevir 49 opioid naïve 49 Phillips DiPisa 49 myStaffingPro applicant tracking 49 postapproval 49 Bicifadine 49 aerosolized AAT 49 GCP compliant 49 Triolex 49 midstage clinical trials 49 trastuzumab emtansine T DM1 49 budesonide foam 49 HIV integrase inhibitors 49 OHR/AVR# 49 iPrEx 49 www.sematech.org 49 CRD5 49 PRIMO CABG 49 eritoran 49 rotavirus shingles 49 Phase III registrational 49 AZILECT R 49 retaspimycin 49 LymphoStat B Phase 49 LymphoStat B belimumab 49 integrase inhibitor 49 CLARITY study 49 multiple myeloma MM 49 unblind 49 pharmacokinetics PK 49 Onrigin 49 Previstage TM GCC 49 retinal specialists 49 Pertuzumab 49 MEND CABG II 49 UPLYSO 49 Mepact 49 CARE HF 49 gefitinib Iressa 49 HER2 positive cancers 49 Excellarate TM 49 Phase 2b randomized 49 Please visit www.antisoma.com 49 randomized Phase 2b 49 biliary tract cancer 49 polycythemia vera essential thrombocythemia 49 PXD# 49 trastuzumab Herceptin 49 metaglidasen 49 MyVax R 49 resminostat 49 JAK2 inhibitor 49 taxane chemotherapy administered 49 INCB# [001] 49 leukemia lymphoma multiple myeloma 49 initiate Phase IIb 49 TELINTRA R 49 AIR CF1 49 ZYBRESTAT fosbretabulin 49 ThermoDox R 49 GRNOPC1 contains 49 QNEXA 49 teduglutide 49 mg/m2 cohort 49 Solorel ® 49 Phase 1b dose escalation 49 ruxolitinib 49 Zybrestat 49 Stimuvax R 49 PEGylated interferon 49 EORTC 49 metastatic gastric 49 subcutaneous methylnaltrexone 49 Solorel TM 49 Neurostep TM 49 Pimavanserin 49 Bezielle 49 Campath alemtuzumab 49 im peramivir 49 Zemiva TM 49 Elisabeth Lindner CEO 49 demonstrated antitumor activity 49 glufosfamide 49 LungAlert TM 49 Phase 1b clinical 49 Depressed bipolar 49 Gag polymorphisms 49 PS# DARA 49 SIR Spheres 49 dirucotide 49 oral salmon calcitonin 49 ACRIN 49 specified primary endpoint 49 azilsartan medoxomil 49 Budesonide foam crofelemer 49 Cytolin 49 ENDEAVOR IV 49 tivozanib 49 Metametrix 49 metastatic sarcomas 49 placebo controlled clinical trials 49 AIR2 Trial 49 Trovax 48 MEND CABG 48 STRIDE PD 48 PROLARIS 48 vaginally administered lidocaine 48 Amgen Neulasta R 48 Urocidin 48 PrevOnco 48 Clinical Antipsychotic Trials 48 SitePRO 48 orally administered inhibitor 48 #I TM# 48 BIM #A# 48 dose dose escalation 48 multicenter clinical trials 48 Phase Ib clinical trials 48 MCSP respectively 48 CDP# 48 oral rivaroxaban 48 Surgical resection 48 multicentre study 48 VALOR trial 48 bepotastine besilate nasal spray 48 HGS ETR1 48 Phase III metastatic melanoma 48 evaluating T DM1 48 Teysuno 48 dialed Ybarra 48 malignant mesothelioma Alfacell 48 ACOMPLIA R 48 Zolinza 48 taxane resistant 48 chemotherapeutic regimen 48 PRESEPT study 48 Cannabinor 48 compound INCB# 48 peginesatide 48 CME Outfitters 48 BrachySil 48 INTEGRILIN R eptifibatide Injection 48 arzoxifene 48 zileuton CR 48 atrasentan 48 isavuconazole 48 COMFORT II 48 MET amplification 48 deforolimus 48 recurrent squamous cell carcinoma 48 Carfilzomib 48 ADVEXIN therapy 48 HDL Selective Delipidation 48 BREVAGen ™ 48 ACCORD Lipid 48 orBec 48 RELIANT trial 48 targeted anticancer therapies 48 MediGene focuses 48 multicenter randomized clinical 48 PhG alpha 1 48 ALLEN SYMPHONY CHORUS 48 epigenetic therapies 48 ACTIVE W 48 PNP inhibitor 48 dose escalation Phase 48 selective androgen receptor modulator 48 Troxatyl TM 48 thorough QTc 48 visilizumab 48 GnRH antagonist 48 Elocalcitol 48 PraxisDirect 48 Phase IIb 48 Oncogenex 48 mGluR5 antagonists 48 AVERROES 48 tanespimycin 48 PCA3 assay 48 Azedra 48 oncologists surgeons